Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A607438-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $59.90 | |
A607438-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,334.90 | |
A607438-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $279.90 | |
A607438-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,001.90 | |
A607438-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $799.90 | |
A607438-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,119.90 |
Synonyms | Aficamten|Aficamten [INN]|Aficamten [USAN]|2364554-48-1|CK-3773274|B1I77MH6K1|Aficamten [USAN:INN]|UNII-B1I77MH6K1|CHEMBL4847050|WHO 11544|1H-Pyrazole-4-carboxamide, N-((1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-|N-((1R)-5-( |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-1-methylpyrazole-4-carboxamide |
---|---|
INCHI | InChI=1S/C18H19N5O2/c1-3-16-21-17(22-25-16)12-4-6-14-11(8-12)5-7-15(14)20-18(24)13-9-19-23(2)10-13/h4,6,8-10,15H,3,5,7H2,1-2H3,(H,20,24)/t15-/m1/s1 |
InChi Key | IOVAZWDIRCRMTM-OAHLLOKOSA-N |
Canonical SMILES | CCc1onc(n1)c1ccc2c(c1)CC[C@H]2NC(=O)c1cnn(c1)C |
Isomeric SMILES | CCC1=NC(=NO1)C2=CC3=C(C=C2)[C@@H](CC3)NC(=O)C4=CN(N=C4)C |
PubChem CID | 139331495 |
Molecular Weight | 337.38 |
CAS Registry No. | 2364554-48-1 |
---|---|
PubChem CID | 139331495 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B2427173 | Certificate of Analysis | Jan 22, 2024 | A607438 |
B2427175 | Certificate of Analysis | Jan 22, 2024 | A607438 |
B2427176 | Certificate of Analysis | Jan 22, 2024 | A607438 |
B2427177 | Certificate of Analysis | Jan 22, 2024 | A607438 |
B2427178 | Certificate of Analysis | Jan 22, 2024 | A607438 |
B2427179 | Certificate of Analysis | Jan 22, 2024 | A607438 |
B2427180 | Certificate of Analysis | Jan 22, 2024 | A607438 |
B2427181 | Certificate of Analysis | Jan 22, 2024 | A607438 |
B2427182 | Certificate of Analysis | Jan 22, 2024 | A607438 |
B2427200 | Certificate of Analysis | Jan 22, 2024 | A607438 |
B2427201 | Certificate of Analysis | Jan 22, 2024 | A607438 |
B2427202 | Certificate of Analysis | Jan 22, 2024 | A607438 |
1. Argirò A, Zampieri M, Berteotti M, Marchi A, Tassetti L, Zocchi C, Iannone L, Bacchi B, Cappelli F, Stefàno P et al.. (2021) Emerging Medical Treatment for Hypertrophic Cardiomyopathy.. J Clin Med, 10 (5): (589-97). [PMID:33804412] |
2. Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, Hwee DT, Wu Y, Wang J, Chin ER et al.. (2021) Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy.. J Med Chem, 129 (3): (589-97). [PMID:34606259] |
3. Alsulami K, Marston S. (2020) Small Molecules acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases.. Int J Mol Sci, 21 (24): (589-97). [PMID:33339418] |